000			07210nam a22003975i 4500
710	2		_aSpringerLink (Online service) _0Local _9106996
999			_c86551 _d86551 _x1
001			86551
003			ES-MaUEC
005			20230207040604.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			161004s2016 sz | s |||| 0|eng d
020			_a9783764385507
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRB131 _b2016 EB
245	1	0	_aCompendium of Inflammatory Diseases _cedited by Michael J Parnham
264		1	_aBasel _bSpringer Basel _c2016
300			_a1 recurso en línea _b218 ilustraciones, 147 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aAdhesion molecules of neutrophils -- Anaphylaxis (Immediate hypersensitivity): from old to new mechanisms -- Antiviral Responses -- Autophagy and Inflammation -- Basophils -- Cell signalling in neutrophils -- Co-stimulatory Receptors -- Dendritic Cells -- GILZ-Related Regulation of Inflammation -- Glial Cells -- Immunoglobulin receptors and inflammation.-Inflammation and autoimmunity -- Inflammatory Bowel Disease Models in Animals -- Leukocyte Recruitment -- Lymphocyte homing and trafficking -- Macrophage heterogeneity during inflammation -- Mast Cells -- Mechanisms of Macrophage Migration in 3-Dimensional Environments -- Microvascular Responses to Inflammation -- Modulation of inflammation by key nutrials -- Natural Killer Cells -- Neutrophil Extracellular Traps -- Neutrophil oxidative burst -- Obesity and Inflammation -- Osteoclasts in Inflammation -- Parasitism: A Unique Lifestyle Reflecting Dynamic Parasite- and Host(s)-Co-driven Processes -- Platelet, Endothelium, and Inflammation -- Regulatory T cells -- Sepsis Models in Animals -- Skin inflammation models in animals -- Th17 Response -- Toll-Like Receptors -- Angiogenesis Inhibitors -- Anti-asthma Drugs, Overview -- Anti-histamines -- Anti-muscarinics -- Antibiotics as anti-inflammatory drugs -- Antimalarial Drugs -- Azathioprine/Thiopurines -- Beta2 Agonists -- CD 20 Inhibitors Rituximab -- CD80/86 Inhibitors -- Chromones Cromoglycate and Nedocromil -- Colony stimulating factor therapeutics -- Corticosteroids -- Coxibs -- Disease-Modifying Anti-Rheumatic Drugs -- Fenamates -- Flavonoids as anti-inflammatory agents -- Gold Complexes -- Interleukin 1 Inhibitors -- Interleukin 12/23 Inhibitors: Ustekinumab Interleukin-6 Inhibitor Tocilizumab -- Leflunomide -- Medicinal Fatty Acids -- Methotrexate.-NO-donating anti-inflammatory drugs -- Non-steroidal anti-inflammatory drugs -- Phosphodiesterase-4 inhibitors -- Propionic Acid Derivative Drugs (Profens) -- Salicylates -- Sulfasalazine and Related Drugs -- Tetracyclines -- Theophylline -- TNF Inhibitors -- Acute exacerbations of airway inflammation -- Allergic Disorders -- Alzheimer's Disease -- Antiphospholipid antibody syndrome -- Asthma -- Atopic dermatitis -- Autoinflammatory syndromes -- Behcets disease -- Bronchiolitis obliterans -- Cancer and inflammation -- Cogans syndrome -- COPD -- Diabetes type I -- Diabetes type II -- Diffuse panbronchiolitis -- Gaucher's disease -- Genetic susceptibility to inflammatory diseases -- Gout -- Graft vs Host Disease -- Granulomatosis with Polyangiitis (GPA) -- Graves disease.-Guillaine-Barre disease -- Henoch-Schönlein Purpura -- Idiopathic Thrombocytopenic Purpura -- Inflammatory bowel disease -- Juvenile idiopathic arthritis -- Kawasaki Disease -- Lyme disease -- Osteoarthritis.-Osteoarthritis Genetics -- Polymyositis and Dermatomyositis -- Rheumatic Fever -- Rheumatoid arthritis -- Role of Cell Therapy in Autoimmune Disease -- Sarcoidosis -- Sepsis -- Spondylarthropathies -- ACKR3 -- Adhesion molecules -- Alarmins -- Antibacterial Host .-Defense Peptides -- Bacterial Lipopolysaccharide.-Biofilm -- Bone Morphogenetic Proteins in Inflammation -- C5a Receptors -- CCL18 -- CCR1 -- Ceramide 1-Phosphate: A Mediator of Inflammatory Responses -- Complement System -- CXCL4 und CXCL4L1 -- CXCR1 and CXCR2 and Ligands -- CXCR3 and its Ligands -- Cytokines -- Cytolytic Granules -- Foxp3 -- Heat Shock Proteins -- Histamine -- IFNgamma -- IkappaB -- Inflammasomes -- Interleukin 1 -- Interleukin 10 -- Interleukin 12 -- Interleukin 17 -- Interleukin 18 -- Interleukin 18 Binding Protein -- Interleukin 2 -- Interleukin 22 -- Interleukin 23 -- Interleukin 27 -- Interleukin 32 -- Interleukin 36 Cytokines -- Interleukin 4 and the related cytokines (Interleukin 5 and Interleukin 13) -- Interleukin 6 -- Interleukin 9 -- Interleukin-33 -- Janus Kinases (JAKs)/STAT Pathway -- Kinins -- Leukotrienes -- Mammalian Target of Rapamycin (mTOR) -- MAP Kinase Pathways -- NFkappaB -- Nitric oxide -- Nuclear Receptor Signaling in the Control of Inflammation -- Pathogen-Associated Molecular Patterns (PAMPs) -- Pentraxins -- Prostanoids -- Protease-Activated Receptors -- Reactive oxygen species -- Substance P in Inflammation -- TGF-b superfamily cytokine MIC-1/GDF15 in health and inflammatory diseases -- TNFalpha -- Type I Interferons.
520			_aInflammation has become one of the most exciting and rewarding areas of medical research. Recent years have seen a revolution in our understanding of how blood and tissue cells interact and of the intracellular mechanisms controlling their activation. This has revealed the underlying inflammatory pathology of many diseases and provided multiple new targets for anti-inflammatory and immunomodulatory therapy. The Encyclopedia of Inflammatory Diseases will cover the following areas: Inflammatory Processes and Cells Inflammatory Diseases Mediators of Inflammation Pharmacology of Inflammation Since inflammatory diseases and their therapy cover a broad range of scientific and medical fields, the encyclopedia will be co-edited by four international experts, a clinician and three researchers from the disciplines of immunology, biochemistry, and pharmacology, in this way providing students, basic and clinical scientists and practitioners in academia, hospitals and industry with valuable interlinked information. This living project will serve as a reliable and comprehensive data pool for everybody working in inflammation research. Owing to its dynamic nature, it will grow with time and future editions, becoming an indispensible source of information for academia, clinical practitioners and industry.
988	0	0	_aEBOOK, EBSPRINGER
650		7	_9673642 _aInflamación _2embne _xAspectos inmunológicos
650		7	_aInmunología _0comprobar BNE19900958507 _2embne _9138330
650		7	_aToxicología _2embne _9140328
700	1		_aParnham, Michael J. _eeditor literario _9100348 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-7643-8550-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783764385507
907			_a.b12958293 _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11615771 _z30-06-17
998			_b05/2020 _dz _eu _feng _gsz _h0